GSK Bio
NEWS
Shares of OncoMed Pharmaceuticals are falling this morning after the company announced that Celgene has walked away from a deal to license the company’s bispecific antibody navicixizumab.
Boehringer Ingelheim announced earlier this week that Christopher Corsico was leaving the company, effective December 31. Today it was announced that Corsico will join GSK to take on the new role of senior vice president of development.
A second former GlaxoSmithKline scientist has pled guilty to stealing trade secrets as part of a scheme to benefit a startup China-based pharmaceutical company he helped establish.
Arix Bioscience plc today announced that industry veteran Arthur Pappas has been appointed as Non-Executive Director to the Arix Board of Directors.
Vectura regaining momentum with continued inhaled revenue and adjusted EBITDA growth
Days after receiving a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on COPD treatment, GlaxoSmithKline released data that showed the same medication was a superior treatment in severe eosinophilic asthma in patients with similar blood eosinophil counts.
As part of an earlier announced restructuring program, UK-based GlaxoSmithKline is laying off 650 staffers in the U.S. GlaxoSmithKline employees approximately 15,000 people in the U.S.
Paris-based Sanofi settled corruption charges with the U.S. Securities and Exchange Commission (SEC) for more than $25 million. Sanofi is far from the first pharma company to be accused of bribery.
Two years after charges were filed by the federal government, former GlaxoSmithKline researcher Yu Xue pled guilty to a single conspiracy charge related to emailing company trade secrets that would have been used to set up competing companies in China.
JOBS
IN THE PRESS